KBY Biotech Indexv0.0.34
Search
← Pipeline|THI-6273

THI-6273

Phase 2
By Third Rock
Source: Trial-derived·Trials: 2
Modality
Gene Therapy
MOA
BCMA ADC
Target
CD19
Pathway
Fibrosis
Huntington'sACCFSGS
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
~Apr 2022
→ ~Jul 2023
Phase 2
Oct 2023
→ Jun 2024
Phase 2Current
NCT04636483
1,124 pts·Huntington's
2024-06→TBD·Completed
NCT03657309
2,922 pts·Huntington's
2023-10→TBD·Not yet recruiting
4,046 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q42024Q2
P2
Not yet…
P2
Complet…
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT04636483Phase 2Huntington'sCompleted1124PASI75
NCT03657309Phase 2Huntington'sNot yet recr...2922NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-8662PfizerNDA/BLACD19GLP-1ag
NVS-6974NovartisPreclinicalCD19HPK1i
VoxarasimodMerck & CoPhase 1/2CD19AuroraAi
AZN-3724AstraZenecaPreclinicalPSMABCMA ADC
OlpatinibGSKPreclinicalPD-L1BCMA ADC
GIL-9779Gilead SciencesPhase 1IL-17ABCMA ADC
SematenlimabSamsung BiologicsPhase 3PI3KαBCMA ADC
TirarelsinTG TherapeuticsNDA/BLACD19IL-17i
TixatapinarofRecursionApprovedFGFRBCMA ADC
TerazumabRecursionPhase 3AHRBCMA ADC